Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
Many trademarks may include non-protectable elements, which describe the type of goods these marks are…
Mongolia stands out as a rapidly developing market, representing significant opportunities for both East Asian…
Sega Corporation, a well-known Japanese video game producer has entered in an agreement with a…
The Eurasian Patent Organization will be raising the fees for several services starting from February…
In 1995, the Eurasian Patent Convention (EAPC) was established to create a unified patent space,…